Rx-to-OTC switch, meeting demand for more natural OTC products and expanding in emerging markets will help GlaxoSmithKline’s standalone consumer health business grow faster than the market when it launches later this year, according to CEO designate Brian McNamara.
Speaking at GSK’s capital markets day, McNamara said the standalone business – which will be called Haleon – was expected...







